Skip to main content

AMGN

Stock
Health Care
Drug Manufacturers - General

Performance overview

AMGN Price
Price Chart

Forward-looking statistics

Beta
0.45
Risk
24.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees26K
Market cap$163.6B

Fundamentals

Enterprise value$198.7B
Revenue$34.1B
Revenue per employee—
Profit margin17.39%
Debt to equity924.46

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$10.98
Dividend per share$9.52
Revenue per share$63.49
Avg trading volume (30 day)$856M
Avg trading volume (10 day)$1B
Put-call ratio—

Macro factor sensitivity

Growth+0.3
Credit+2.7
Liquidity+0.2
Inflation-2.3
Commodities-0.6
Interest Rates-0.6

Valuation

Dividend yield3.19%
PEG Ratio14.43
Price to sales4.70
P/E Ratio14.43
Enterprise Value to Revenue5.82
Price to book25.84

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend dayMay 16, 2025

News

Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, Amgen (AMGN) closed at $295.18, marking a -1.73% move from the previous day.

Zacks Investment Research (July 11, 2025)
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 2, 2025)
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently.

Benzinga (June 24, 2025)
What's Happening With Amgen Stock?

Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.

Forbes (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free